Effects of soy protein isolate on bone mineral density and physical performance indices in postmenopausal women - A 2-year randomized, double-blind, placebo-controlled trial

Menopause

Volumn 16, Issue 2, 2009, Pages 320-328

  Vupadhyayula, Phani M ^a   Gallagher, J C ^a   Templin, Thomas ^a   Logsdon, Susannah M ^a   Smith, Lynette M ^b  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bone mineral density; Isoflavones; Physical performance; Postmenopausal; Randomized controlled trial; Soy

Indexed keywords

CASEIN; ISOFLAVONE DERIVATIVE; SOYBEAN PROTEIN;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR NECK; HUMAN; HUMAN EXPERIMENT; LUMBAR SPINE; METABOLIC PARAMETERS; NORMAL HUMAN; OSTEOLYSIS; PATIENT COMPLIANCE; PHYSICAL PERFORMANCE; POSTMENOPAUSE; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; WHEY;

BONE DENSITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; MOTOR ACTIVITY; POSTMENOPAUSE; SOYBEAN PROTEINS; TREATMENT OUTCOME; VEGETABLE PROTEINS;

EID: 67649376685     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181844893     Document Type: Article

References (44)

1. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1992;327:620-627.
2. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2:285-289.
3. Middleton ET, Steel SA. The effects of short-term hormone replacement therapy on long-term bone mineral density. Climacteric 2007;10:257-263.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
6. Kuiper GG, Lemmen JG, Carlsson B. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998;139:4252-4263.
7. Setchell KD. Soy isoflavones - benefits and risks from nature's selective estrogen receptor modulators (SERMs). J Am Coll Nutr 2001; 20(5 Suppl):354S-362S.
8. Arjmandi BH, Birnbaum R, Goyal NV, et al. Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. Am J Clin Nutr 1998;68:1364S-1368S.
9. Arjmandi BH, Getlinger MJ, Goyal NV, et al. Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats. Am J Clin Nutr 1998;68(6 Suppl):1358S-1363S.
10. Draper CR, Edel MJ, Dick IM, Randall AG, Martin GB, Prince RL. Phytoestrogens reduce bone loss and bone resorption in oophorectom-ized rats. J Nutr 1997;127:1795-1799.
11. Blair HC, Jordan SE, Peterson TG, Barnes S. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J Cell Biochem 1996;61:629-637.
12. Dalais FS, Rice GE, Wahlqvist ML, et al. Effects of dietary phytoestrogens in postmenopausal women. Climacteric 1998;1:124-129.
13. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68 (6 Suppl):1375S-1379S.
14. Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 2000;72:844-852.
15. Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 2001;8:259-265.
16. Harkness LS, Fiedler K, Sehgal AR, Oravec D, Lerner E. Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. J Womens Health (Larchmt) 2004;13:1000-1007.
17. Arjmandi BH, Lucas EA, Khalil DA, Devareddy L, Smith BJ, McDonald J. One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr J 2005;4:8.
18. Morabito N, Crisafulli A, Vergara C, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 2002;17:1904-1912.
19. Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, Holm-Jensen T. Soymilk or progesterone for prevention of bone loss - a 2 year randomized, placebo-controlled trial. Eur J Nutr 2004;43:246-257.
20. Anderson JJ, Chen X, Boass A, et al. Soy isoflavones: no effects on bone mineral content and bone mineral density in healthy, menstruating young adult women after one year. J Am Coll Nutr 2002;21:388-393.
21. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 2004;292:65-74.
22. Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect of soy protein isolate on bone metabolism. Menopause 2004; 11:290-298.
23. Yoles I, Yogev Y, Frenkel Y, Nahum R, Hirsch M, Kaplan B. Tofupill/Femarelle (DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss. Menopause 2003; 10:522-525.
24. Newton KM, LaCroix AZ, Levy L, et al. Soy protein and bone mineral density in older men and women: a randomized trial. Maturitas 2006;55:270-277.
25. Evans EM, Racette SB, Van Pelt RE, Peterson LR, Villareal DT. Effects of soy protein isolate and moderate exercise on bone turnover and bone mineral density in postmenopausal women. Menopause 2007;14(3 Pt 1):481-488.
26. Marini H, Minutoli L, Polito F, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med 2007; 146:839-847.
27. Heaney RP. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 1994;9:1515-1523.
28. Samson MM, Meeuwsen IB, Crowe A, Dessens JA, Duursma SA, Verhaar HJ. Relationships between physical performance measures, age, height and body weight in healthy adults. Age Ageing 2000;29: 235-242.
29. Cauley JA, Petrini AM, LaPorte RE, et al. The decline of grip strength in the menopause: relationship to physical activity, estrogen use and anthropometric factors. J Chronic Dis 1987;40:115-120.
30. Phillips SK, Rook KM, Siddle NC, Bruce SA, Woledge RC. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci (Lond) 1993;84:95-98.
31. Skelton DA, Phillips SK, Bruce SA, Naylor CH, Woledge RC. Hormone replacement therapy increases isometric muscle strength of adductor pollicis in post-menopausal women. Clin Sci (Lond) 1999;96: 357-364.
32. Kok L, Kreijkamp-Kaspers S, Grobbee DE, Lampe JW, van der Schouw YT. Soy isoflavones, body composition, and physical performance. Maturitas 2005;52:102-110.
33. Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 1993;46:153-162.
34. Bohannon RW, Schaubert KL. Test-retest reliability of grip-strength measures obtained over a 12-week interval from community-dwelling elders. J Hand Ther 2005;18:426-427.
35. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
36. Fitzmaurice GM, Laird NM. Generalized linear mixture models for handling nonignorable dropouts in longitudinal studies. Biostatistics 2000;1:141-156.
37. Arjmandi BH, Khalil DA, Smith BJ, et al. Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion. J Clin Endocrinol Metab 2003;88: 1048-1054.
38. Gallo D, Zannoni GF, Apollonio P, et al. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectom- ized rat model of menopause: effects on bone, uterus, and lipid profile. Menopause 2005;12:589-600.
39. Erlandsson MC, Islander U, Moverare S, Ohlsson C, Carlsten H. Estrogenic agonism and antagonism of the soy isoflavone genistein in uterus, bone and lymphopoiesis in mice. APMIS 2005;113:317-323.
40. 41Ca. J Clin Endocrinol Metab 2007;92:577-582.
41. Taaffe DR, Luz Villa M, Delay R, Marcus R. Maximal muscle strength of elderly women is not influenced by oestrogen status. Age Ageing 1995;24:329-333.
42. Greeves JP, Cable NT, Reilly T, Kingsland C. Changes in muscle strength in women following the menopause: a longitudinal assessment of the efficacy of hormone replacement therapy. Clin Sci (Lond) 1999;97:79-84.
43. Preisinger E, Alacamlioglu Y, Saradeth T, Resch KL, Holzer G, Metka M. Forearm bone density and grip strength in women after menopause, with and without estrogen replacement therapy. Maturitas 1995;21:57-63.
44. Meeuwsen IB, Samson MM, Verhaar HJ. Evaluation of the applicability of HRT as a preservative of muscle strength in women. Maturitas 2000;36:49-61.